Heartgard

Important Safety Information

HEARTGARD® Plus (ivermectin/pyrantel) is well tolerated. All dogs should be tested for heartworm infection before starting a preventive program. Following the use of HEARTGARD Plus, digestive and neurological side effects have rarely been reported. For more information, click here for full prescribing information or visit HEARTGARD.com.

NexGard® (afoxolaner) is for use in dogs only. The most frequently reported adverse reactions include vomiting, itching, lethargy, diarrhea, and lack of appetite. The safe use of NexGard in pregnant, breeding, or lactating dogs has not been evaluated. Use with caution in dogs with a history of seizures or neurologic disorders. For more information, contact your veterinarian, visit NexGardForDogs.com or click here for full prescribing information.

* Data on file at Boehringer Ingelheim.

** Data on file at Boehringer Ingelheim.

† Data on file at Boehringer Ingelheim.

†† Heartworm Parasite Prevalence Maps. Companion Animal Parasite Council. Accessed August 4, 2021. http://capcvet.org/maps/#2020/all/heartworm-canine/dog/united-states

‡ Lynn RC, Duquette RA. Chapter 6. Antiparasitic Drugs. In: Bowmann DD, ed. Georgis’ Parasitology for Veterinarians. 11th ed. St. Louis, M: Elsveier;2021:286-348.

◊ HEARTGARD® Plus (ivermectin/pyrantel) Chewables [Freedom of Information Summary; NADA140-971]. Duluth, GA: Boehringer Ingelheim Animal Health USA Inc.

◊◊ Current Canine Guidelines for the Prevention, Diagnosis and Management of Heartworm Infections in Dogs 2018. American Heartworm Society. https://www.heartwormsociety.org/images/pdf/2018-AHS-Canine-Guidelines.pdf. Accessed Sept 14, 2021.

HEARTGARD® and the Dog & Hand logo® are registered trademarks of Boehringer Ingelheim Health USA Inc. NexGard® is a registered trademark and FRONTLINE VET LABS™ is a trademark of the Boehringer Ingelheim Group. All other trademarks are property of their respective owners. ©2022 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved.